Navigation Links
VCU receives NIH grant to examine the biology of allergic disease
Date:7/17/2013

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease.

The five-year grant will be led by John Ryan, Ph.D., associate professor in the Department of Biology in the VCU College of Humanities and Sciences. Ryan and his colleagues will investigate how interleukin-10, IL-10, controls mast cell homeostasis.

IL-10 is a type of signaling protein known for its anti-inflammatory effects. Mast cells, which are known to play a central role in asthma and allergy, are packed with granules containing histamine and are found in nearly all tissues, with the exception of blood. Inflammatory substances such as histamine, heparin and a number of cytokines are rapidly released into tissues and blood when a mast cell is activated. This results in an allergic response.

"This project is helping us understand how mast cells, the causative agent of allergic disease and asthma, are naturally regulated," said Ryan.

"Our data suggest that factors produced by other white blood cells, especially the cytokine IL-10, function as feedback regulators to prevent mast cell-mediated inflammation from becoming chronic. We have recently found that genetic background can alter responsiveness to this feedback regulation, which could predispose individuals to chronic allergic diseases like asthma."

Earlier this year, Ryan received a $1.8 million NIH National Institute of Allergy and Infectious Diseases grant for another project investigating the molecular interaction of two enzymes and their involvement in inflammation. This project is designed to understand how the production of autoantibodies leads to arthritis.

"We are specifically interested in how two enzymes, tyrosine kinases called Fyn and Lyn, appear to be activated inside immune cells," Ryan said. "We believe that these two enzymes are an antagonistic pair, with Fyn promoting and Lyn antagonizing the onset of arthritis."

Understanding this pathway could lead to the design of new therapies for rheumatoid arthritis, he said. The project is also five years.


'/>"/>

Contact: Sathya Achia Abraham
sbachia@vcu.edu
804-828-1231
Virginia Commonwealth University
Source:Eurekalert

Related biology news :

1. Carnegies Chris Field receives Max Planck Research Prize
2. Penn receives prestigious national award for breakthrough in gene therapy
3. Peihua Jiang receives Ajinomoto Award for Young Investigators in Gustation from AChemS
4. Forsyth Institute receives $4.1 million grant for new center
5. Einstein receives $12 million grant to develop device for preventing HIV infection
6. Wayne State vision restoration technology receives Notice of Allowance for US patent app
7. BU researcher receives highest honor from the National Birth Defects Prevention Network
8. Geneticist Svante Pääbo receives the $500,000 Gruber Genetics Prize
9. Artificial retina receives FDA approval
10. NTU Provost receives prestigious Imperial College fellowship joining the ranks of top UK scientists
11. Xenon Receives a Milestone Payment for Marketing Approval of Glybera in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: